Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/01/12 22:20:45」(JST)

wiki en

Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis. It is marketed by Novartis under the brand name Aredia. In India, it is marketed by Curacell Biotech under the brand name Pamimed.

Uses

It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels. It is also used as an experimental treatment of the bone disorder known as Osteogenesis Imperfecta. It has been studied in the treatment of Complex Regional Pain Syndrome.^[1]

Administration

Intravenous, usually 90 mg monthly. 30 mg, 60 mg, 90 mg and for hospitals, 120 mg vials are available, mixed with mannitol.

Side effects

Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.^[2]

Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.

References

^ Kubalek, O. Fain, J. Paries, A. Kettaneh, M. Thomas (2001). "Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases.". Rheumatology 40 (12): 1394–1397. doi:10.1093/rheumatology/40.12.1394. PMID 11752511.
^ Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy.". Am J Hematol 81 (1): 73–5. doi:10.1002/ajh.20481. PMID 16369966.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 高カルシウム血症の治療 treatment of hypercalcemia
2. 多発性骨髄腫患者のビスフォスフォネート製剤の使用 the use of bisphosphonates in patients with multiple myeloma
3. 乳癌による骨転移のマネージメントにおける骨吸収抑制剤 osteoclast inhibitors in the management of bone metastases from breast cancer
4. 骨形成不全症：管理および予後 osteogenesis imperfecta management and prognosis
5. 閉経後女性における骨粗鬆症に対するビスホスホネート投与 the use of bisphosphonates in postmenopausal women with osteoporosis

English Journal

Diphosphonate Immobilization on Hydroxyapatite-Coated Titanium-Method Description.

Guimarães MB, Bueno RS, Guimarães Blaya MB, Hirakata LM, Hübler R.Source*Associate Professor of Prosthodontics, School of Dentistry, Centro Universitário Franciscano, Santa Maria, Rio Grande do Sul, Brazil. †Specialist in Implant Dentistry, SOERGS, Porto Alegre, RS, Brazil. ‡Specialist in Orthodontics, PhD in Dental Materials, School of Dentistry, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil. §Associate Professor of Dental Materials, Department of Prosthodontics, School of Dentistry, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil. ¶Assistant Professor of Physics, School of Physics, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
Implant dentistry.Implant Dent.2013 Jun 3. [Epub ahead of print]
PURPOSE:: The aim of this study was to promote the immobilization of a bone activity biomodulator (diphosphonate) on titanium, commonly used in implant dentistry, to provide a local method of delivering this drug during the osseointegration process. METHODS:: The implant material used in this study
PMID 23736311

Manipulation of autophagy in cancer cells: an innovative strategy to fight drug resistance.

Aredia F, Scovassi AI.SourceIstituto di Genetica Molecolare CNR, Via Abbiategrasso 207, 27100 Pavia, Italy.
Future medicinal chemistry.Future Med Chem.2013 Jun;5(9):1009-21. doi: 10.4155/fmc.13.85.
Autophagy is a catabolic process activated by stress conditions and nutrient deprivation, to which it reacts by promoting the degradation of damaged organelles and misfolded/aggregated proteins, as well as generating new energetic pools. Paradoxically, in cancer cells, which signal the dangerous mic
PMID 23734684

Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using micro-computed tomography.

Matuszewski L, Turżańska K, Matuszewska A, Jabłoński M, Polkowska I, Mazurkiewicz T.SourcePaediatric Orthopedic and Rehabilitation Clinic, Medical University of Lublin, Lublin, Poland, lukasz.matuszewski@am.lublin.pl.
International orthopaedics.Int Orthop.2013 Jun;37(6):1187-93. doi: 10.1007/s00264-013-1855-z. Epub 2013 Mar 16.
PURPOSE: Bisphosphonates (BPs) are antiresorptive drugs typically used to inhibit bone resorption. The latest reports show that BPs play an important role in not only achieving better bone mineral density but also in improving bone microarchitecture. The mechanism of action of the BPs is complex and
PMID 23503639

Japanese Journal

Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws : A growing epidemic

MARX RE.
J. Oral Maxillofac. Surg. 61, 1115-1118, 2003
NAID 30015173105

PSKを併用した bisphosphonate (Aredia) の乳癌細胞株 (c-SST-2) に対する抗腫瘍効果の検討

天野定雄
Biotherapy 15, 259-262, 2001
NAID 80012428277

Optimising Treatment of Bone Metastases by Aredia^<TM> and Zometa^<TM>

COLEMAN Robert E.
Breast cancer : the journal of the Japanese Breast Cancer Society 7(4), 361-369, 2000-10-01
NAID 10007065983

Related Pictures

Aredia Aredia Drugs reference index « Aredia » Synonyms: Aredia pamidronate disodium for AREDIA Aredia prescription drug /side effects Aredia intravenous Mihama oc by Aredia

★リンクテーブル★

リンク元

「パミドロン酸」

Pamidronic acid
Systematic (IUPAC) name
	(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a601163
Pregnancy; category	AU: B3; US: D (Evidence of risk); ;
Legal status	UK: POM (Prescription only); US: ℞-only;
Routes of; administration	Intravenous
Pharmacokinetic data
Bioavailability	n/a
Protein binding	54%
Metabolism	Nil
Biological half-life	28 ± 7 hours
Excretion	Renal
Identifiers
CAS Number	40391-99-9
ATC code	M05BA03
PubChem	CID: 4674
IUPHAR/BPS	7259
DrugBank	DB00282
ChemSpider	4512
UNII	OYY3447OMC
KEGG	D07281
ChEMBL	CHEMBL834
Chemical data
Formula	C3H11NO7P2
Molecular mass	235.07 g/mol
	SMILES O=P(O)(O)C(O)(CCN)P(=O)(O)O ;
	InChI InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11) ; Key:WRUUGTRCQOWXEG-UHFFFAOYSA-N ;
(verify)

　　[★]

英: pamidronate、pamidronic acid
同: パミドロネート、パミドロン酸二ナトリウム pamidronate disodium
商: アレディア Aredia

他に分類されない代謝性医薬品

[Kubalek-1] Kubalek, O. Fain, J. Paries, A. Kettaneh, M. Thomas (2001). "Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases.". Rheumatology 40 (12): 1394–1397. doi:10.1093/rheumatology/40.12.1394. PMID 11752511.

[Zarychanski-2] Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy.". Am J Hematol 81 (1): 73–5. doi:10.1002/ajh.20481. PMID 16369966.

匿名

検索

案内

案内

Aredia